.@GSK focus on its R&amp;D pipeline has come into play amidst the ongoing pandemic, with long-acting HIV drug, Cabotegravir showcasing superior clinical efficacy over market-leader Gilead’s Truvada. Note published by @Alphavalue #shares #stocks
https://t.co/XmVXeXCftC https://t.co/dkuJxYkkJb